⚡️We are pleased to share a new publication with New Pulsatile Ventricle Assist Platform, pVAP: Hemodynamical…
We have a mission!
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
Take a look at our products
Now also available in the
App Store, download here:
SEE OUR
Facts & Figures
Registrations
> 50 countries approved registrations
Cases
> 175 shared cases on LinkedIn; > 400 reported cases
> 1.300 iVAC 2L sold
> 35 distributor agreements
Hospitals
> 45 hospitals use iVAC 2L on a regular base; > 9 Centers of Excellence.
Patients
> 600 patients world wide treated by iVAC 2L
Clinical evidence
> 30 publications
Indication
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
21-05-2024
EuroPCR May 2024
06-05-2024
EuroPCR sessions featuring iVAC 2L Technology 14-17 May 2024
25-04-2024
First TEACH course iVAC 2L in Italy hosted by Dr. Gioel Gabrio Secco, Ospedale Civile Ss. Antonio e Biagio e Cesare Arrigo, Alessandria
10-04-2024
Top 50 Most Innovative Companies to Watch 2024
MEET OUR
Medical advisors
Clinical programme supported by leading cardiologists